Keros Therapeutics Began Phase 2 Duchenne Trial
The company has dosed its first patient in a mid-stage trial evaluating rinvatercept for Duchenne muscular dystrophy.
Updated on Sept. 28, 2026 in Biotech
Live Poll
Are pharmaceutical companies doing enough to develop and provide treatment options for rare diseases?
Keros Therapeutics has initiated a Phase 2, open-label, multi-cohort clinical trial for its drug candidate rinvatercept. The research evaluates the safety and potential efficacy of the treatment in late-ambulatory and early non-ambulatory patients with Duchenne muscular dystrophy.
Why it matters
The trial seeks to validate the therapeutic potential of targeting myostatin and activin A pathways in humans following preclinical data supporting this approach. This development moves the compound into active clinical evaluation for a condition with high unmet medical needs.
The clinical trial is registered under identifier NCT07704099 and covers an open-label, multi-cohort design. It measures pharmacokinetics and anti-drug antibodies alongside functional improvements in skeletal muscle, motor, cardiac, and pulmonary performance.
The players
Keros Therapeutics
A Lexington, Massachusetts-based biotech company focused on developing TGF-beta superfamily protein therapeutics for muscle and hematologic disorders.
The details
Rinvatercept acts as a ligand trap, a protein designed to bind to specific signaling molecules in the blood to prevent them from interacting with their natural receptors. By sequestering myostatin—a protein that inhibits muscle growth—and activin A, the drug aims to mitigate the muscle degeneration characteristic of Duchenne muscular dystrophy. This study assesses the drug's safety, tolerability, and physiological impact on patients.
Timeline
September 28, 2026: The first patient was dosed in the Phase 2 clinical trial.
First half of 2027: Keros Therapeutics expects to release initial trial data.
The Tech Race
This trial joins the broader competitive landscape of muscle-targeting therapies that utilize ligand traps to modulate pathways like myostatin and activin A. It represents a specific attempt to advance this mechanism beyond preclinical models and into a registered Phase 2 clinical program.
The trial is currently limited to selected late-ambulatory and early non-ambulatory patients participating in the study. Potential benefits for the broader Duchenne population remain dependent on successful trial milestones and future regulatory approval phases.
The takeaway
Keros Therapeutics has transitioned its ligand trap candidate from preclinical research into human testing for Duchenne muscular dystrophy. Stakeholders should track the release of initial Phase 2 trial data, expected in the first half of 2027, to evaluate the drug's safety and functional efficacy profile.
What happens next
Keros Therapeutics anticipates the release of initial data from the clinical trial in the first half of 2027.
Further reading
For more on the current landscape of experimental muscle therapies, explore our Biotech section.
Live Poll
Are pharmaceutical companies doing enough to develop and provide treatment options for rare diseases?
